Definium Therapeutics Drops 9% Ahead of DT120 Anxiety Trial Data This Week

2 articles · Updated · Yahoo Finance · Aug 11

Definium shares fell 9% Tuesday, putting the stock on track for its worst day since early November as investors turned cautious before a pivotal clinical readout due this week.
The Voyage late-stage study is testing DT120 as a one-time treatment for generalized anxiety disorder, with a second anxiety data release scheduled for September.
Expectations are high because DT120 posted strong late-stage depression results in June, showing rapid and durable symptom relief against placebo with a clean safety profile.
Definium said earlier this month it held about $1.1 billion in cash after fundraising, enough to fund operations into 2030 as it continues anxiety studies and plans a PTSD trial next year.
Retail sentiment on Stocktwits still swung to 'extremely bullish' over the past 24 hours, underscoring the split between market caution ahead of the data and trader optimism on the outcome.